Top Markets
#1 Black Phoenix Black Phoenix +167.53%
#2 Islamic Coin Islamic Coin +158.30%
#3 Glidr Glidr +84.34%
#4 Acurast Acurast +29.49%
#5 Test Test +23.70%
#6 Cryptopia Cryptopia +20.92%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.38%
#8 Quantum Resistant Ledger Quantum Resistant Ledger +17.98%
#9 Steem Steem +13.65%
#10 MarsCoin MarsCoin +9.72%
Coin of the day
Black Phoenix Black Phoenix
Instellingen
Taal
DUTCH
Valuta
USD
Thema
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc.

VIAP
Rang in aandelen #41780
VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily... VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily focused on discovering and advancing therapeutic compounds for cardiovascular and metabolic disorders. The firm is building a portfolio of small-molecule drug candidates designed to tackle the root causes of these health issues, such as vascular inflammation, elevated cholesterol and triglyceride levels, and insulin resistance or diabetes. Notable candidates in their development pipeline include: VIA-3196: A liver-specific thyroid hormone receptor (THR) beta agonist, poised for Phase 1 clinical studies. This drug aims to mitigate dyslipidemia, addressing high LDL cholesterol, elevated triglycerides, and Lp(a) levels. A Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor: Currently in preclinical development for treating type 2 diabetes, with promising potential for weight management and other lipid disorders. VIA-2291: A 5-Lipoxygenase inhibitor that has successfully completed its third Phase 2 clinical trial. Its purpose is to target atherosclerotic plaque, a significant contributor to heart attacks, strokes, and various other vascular diseases. VIA Pharmaceuticals has also forged two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. These collaborations pertain to their THR beta agonist program and several compounds from their preclinical DGAT1 metabolic disorders initiative. Established in 2004, the company's headquarters are located in San Francisco, California.
Aandeelprijs
$0.0005
Laatst gesynchroniseerd: 2026-08-11
Marktkapitalisatie
$10.28K
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel VIA Pharmaceuticals, Inc. (VIAP)

Categorie

Healthcare
Dividendgeschiedenis van VIA Pharmaceuticals, Inc. (VIAP)
VIA Pharmaceuticals, Inc. (aandelsymbool: VIAP) heeft in totaal 0 dividenduitkeringen gedaan.
De som van alle dividenden (aangepast voor aandelensplitsingen) is: 0.00
Dividendrendement (TTM): 0
Dividendbetalingen voor VIA Pharmaceuticals, Inc. (VIAP) van 2026 tot 2026
Jaarlijkse dividendbetalingen
Jaar Dividend (aangepast voor aandelensplitsingen) Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Lijst van alle dividendbetalingen
Jaar Dividend Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendbetalingen voor vergelijkbare bedrijven of concurrenten
Bedrijf Aantal dividendbetalingen Land
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
23.00%
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
0.00%
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
0.00%
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
0.00%
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
0.00%
US